Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
Portfolio Pulse from Vandana Singh
Lexaria Bioscience announced additional findings from its human clinical Study HYPER-H21-4, showing significant reductions in pro-inflammatory biomarkers linked to cardiovascular disease after five weeks of treatment with DehydraTECH-processed CBD capsules. The study's primary efficacy and safety objectives were successfully achieved, with no serious adverse events reported.
May 23, 2023 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH-processed CBD capsules demonstrated significant reductions in pro-inflammatory biomarkers linked to cardiovascular disease in a clinical study.
The positive results from Lexaria Bioscience's clinical study indicate that their DehydraTECH-processed CBD capsules could potentially be an effective treatment for reducing pro-inflammatory biomarkers linked to cardiovascular disease. This could lead to increased demand for the product and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH-processed CBD capsules demonstrated significant reductions in pro-inflammatory biomarkers linked to cardiovascular disease in a clinical study.
The positive results from Lexaria Bioscience's clinical study indicate that their DehydraTECH-processed CBD capsules could potentially be an effective treatment for reducing pro-inflammatory biomarkers linked to cardiovascular disease. This could lead to increased demand for the product and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100